IMUNON To Present Abstract Highlighting IMNN-001 Data Based On Immune Biomarker Analysis From Phase 2 OVATION 2 Study At ESMO Gynaecological Cancers Congress 2025

Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001

Simultaneously publication in leading peer-reviewed journal Gynecologic Oncology details IMNN-001's outstanding safety and efficacy across multiple analyses and subgroups

Treatment with IMNN-001 could represent new promise for estimated 40,000 women newly diagnosed with advanced ovarian cancer yearly in EU and 300,000 globally

LAWRENCEVILLE, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract highlighting IMNN-001 data based on an immune biomarker analysis from the Phase 2 OVATION 2 Study in women with newly diagnosed advanced ovarian cancer was accepted for poster presentation at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025, being held June 19-21, 2025 in Vienna, Austria. The abstract, titled "Immune biomarker analysis of the OVATION-2 trial, a randomized Phase I/II study of IL-12 gene therapy IMNN-001 in combination with Neo/Adjuvant Chemotherapy (NACT) in newly-diagnosed advanced Epithelial Ovarian Cancer (EOC)," will be presented by Premal H. Thaker, M.D., Interim Chief of Gynecologic Oncology, David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology, Director of Gynecologic Oncology Clinical Research at Washington University School of Medicine, OVATION 2 Study Chair and Study Chair of the Phase 3 OVATION 3 trial.

IMUNON also recently announced that new positive data from the OVATION 2 Study will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the peer-reviewed journal Gynecologic Oncology. Results include continuous clinically significant improvement in the IMNN-001 treatment group, with median 13-month and 3-month increases in overall and progression-free survival, respectively.

IMNN-001, based on IMUNON's proprietary TheraPlas® technology platform, is an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, enabling cell transfection followed by persistent, local production and secretion of the IL-12 protein in the tumor microenvironment. IL-12 is a powerful pluripotent cytokine known for inducing strong anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation while inhibiting tumor-mediated immune suppression. IMNN-001 is the first and only IL-12 immunotherapy to achieve a clinically effective response including overall survival benefit in frontline treatment in patients with advanced (stage III/IV) ovarian cancer.